PTO-1390 (Rev. 07-2005)

Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER 2035.0240001/RWE

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

INTERNATIONAL APPLICATION NO

US2005/016282	10 May 2005 (10.05.2005)	10 May 2004 (10.05.2004)						
TITLE OF INVENTION Prevention of Arterial Restenosis with Active Vitamin D Compounds								
APPLICANT(S) FOR DO/EO/US Martha J. Whitehouse and Bradford S. Goodwin								
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:								
X This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.								
This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.								
This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.								
The US has been elected (Article 31).								
A copy of the International Application as filed (35 U.S.C. 371(c)(2))								
a. is attached hereto (required only if not communicated by the International Bureau).								
b. X has been communicated by the International Bureau.								
c. is not required, as the application was filed in the United States Receiving Office (RO/US).								
An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).								
a. is attached hereto.								
b. has been previously submitted under 35 U.S.C. 154(d)(4).								
Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))								
a. are attached hereto (required only if not communicated by the International Bureau).								
b. have been communicated by the International Bureau.								
c. have not been made; however, the time limit for making such amendments has NOT expired.								
d. X have not been made and will not be made.								
An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).								
An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).								
An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).								
Items 11 to 20 below concern document(s) or information included:								
An Information Disclosure Statement under 37 CFR 1.97 and 1.98.								
An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.								
A preliminary amendment.								
An Application Data Sheet under 37 CFR 1.76.								
A substitute specification.								
A power of attorney and/or change of address letter.								
A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825.								
A second copy of the published International Application under 35 U.S.C. 154(d)(4).								
A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).								
	of Arterial Restenosis will FOR DO/EO/US Thitehouse and Bradford and Eventh submits to the United States as a FIRST submission of items consists an express request to begin nation and provided the following of the International Application is attached hereto (required is attached hereto (required is not required, as the application is attached hereto. In has been previously submit is attached hereto. In has been previously submit are attached hereto (required is attached hereto. In has been previously submit are attached hereto (required in have not been made; howed in have not been made and we have not been made; hower of the inventor of the inventor of the inventor of the inventor of the sequence of attorney and/or change of the published Internation country of the	of Arterial Restenosis with Active Vitamin D Compound FOR DO/EO/US Phitchouse and Bradford S. Goodwin Powith submits to the United States Designated/Elected Office (DO/EC) Phitchouse and Bradford S. Goodwin Powith submits to the United States Designated/Elected Office (DO/EC) Phitchouse and Bradford S. Goodwin Powith submits to the United States Designated/Elected Office (DO/EC) Phitchouse and Bradford S. Goodwin Powith submits to the United States Designated/Elected Office (DO/EC) Phitchouse a FIRST submission of items concerning a submission of an express request to begin national examination procedures (35 U.S.C. 37 (5), (9) and (21) indicated below. Phitchouse request to begin national examination procedures (35 U.S.C. 37 (6)) Phitchouse request to begin national examination procedures (35 U.S.C. 37 (6)) Phitchouse request to begin national examination procedures (35 U.S.C. 37 (6)) Phitchouse request to begin national examination procedures (35 U.S.C. 37 (6)) Phitchouse request to begin national examination procedures (35 U.S.C. 37 (6)) Phitchouse request to begin national examination allowers. Phitchouse request to begin national examination as filed (35 U.S.C. 37 (6)) Phitchouse request to begin national examinational procedures (35 U.S.C. 37 (6)) Phitchouse required only if not communicated by the International Eureau. Phase been previously submitted under 35 U.S.C. 154(d)(4). Phitchouse proviously submitted under 35 U.S.C. 371(c)(4)). Phitchouse required only if not communicated by the International Eureau. Phase been communicated by the International Bureau. Phitchouse proviously submitted under 35 U.S.C. 371(c)(5)). Phitchouse regular examination of the amendments to the claims under PCT Article 19 (6) Phitchouse and proviously submitted under 37 U.S.C. 371(c)(4)). Phitchouse regular examination of the amendments to the claims under PCT Article 19 (7) Phitchouse and proviously submitted under 37 U.S.C. 371(c)(5)). Phitchouse regular examination of the sequence listing in accordance with PCT Rule 1 (

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, OSPIO to process) an application. Continentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	5 8 Osigne	PCT/US2005/016282			2035.0240001/RWE	
			orporating an Extension	on of Time Und	er 37 C.F.R. § 1.13	6(a)(3); and b.
The follo	owing fees have b	een submitted			CALCULATIONS	PTO USE ONLY
	Basic national fee (37 CFR 1.492(a))\$300				\$ 300	
22. X Exam	nination fee (37 CF					
If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)\$0 All other situations\$200					\$ 0	
23. X Search fee (37 CFR 1.492(b)) If the written opinion of the ISA/US or the International preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)\$0 Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority					\$	
					300	
TOTAL OF 21, 22 and 23 = Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					300	
Total Sheets	Extra Sheets	a Sheets Number of each additional 50 or fraction thereof (round up to a whole number)				
47 - 100 =	0 /50 =		0	× \$250	\$ 0	l
Surcharge of \$130.00 for furnishing any of the search fee, examination fee, or the oath or declaration after the date of commencement of the national stage (37 CFR 1.492(h)).					\$ 0	
CLAIMS	NUMB	ER FILED	NUMBER EXTRA	RATE	\$	
Total claims		42 - 20 =	22	× \$50	\$ 1100	
Independent clair	ms	1 -3=	0	× \$200	\$ 0	
MULTIPLE DEPENDENT CLAIM(S) (if applicable) 0 + \$360					\$ 0	
TOTAL OF ABOVE CALCULATIONS =					\$ 1400	
X Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by ½.					700	
SUBTOTAL =				\$ 700		
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).				\$ 0		
TOTAL NATIONAL FEE =				\$ 700		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$ 0		
TOTAL FEES ENCLOSED =				\$ 700		
					Amount to be refunded:	\$
					Amount to be charged	\$

10/589455

IAP11 Rec'd PCT/PTO 15 AUG 2AGR390 (Rev. 07-2

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. A check in the amount of \$ _ to cover the above fees is enclosed. Please charge my Deposit Account No. in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0036</u>. A duplicate copy of this sheet is enclosed. d. X Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status. SEND ALL CORRESPONDENCE TO: SIGNATURE CUSTOMER NUMBER 26111 Robert W. Esmond NAME 32,893 **REGISTRATION NUMBER**